FDA approves prostate treatment from GSK

Tuesday 15 June 2010

GlaxoSmithKline said that the US Food and Drug Administration has approved its combination treatment for benign prostatic hyperplasia, Jalyn. The drug combines dutasteride and tamsulosin in a single capsule.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom